Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | F2 | P00734 | 1/20 | 0.60 |
| ▸ | PRSS1 | P07477 | 1/20 | 0.60 |
| ▸ | PRSS2 | P07478 | 1/20 | 0.60 |
| ▸ | PRSS3 | P35030 | 1/20 | 0.60 |
| ▸ | TPSAB1 | Q15661 | 1/20 | 0.60 |
| ▸ | TDP1 | Q9NUW8 | 5/20 | 0.58 |
| ▸ | FOLH1 | Q04609 | 3/20 | 0.57 |
| ▸ | PKM | P14618 | 3/20 | 0.56 |
| ▸ | PLCD1 | P51178 | 1/20 | 0.52 |
| ▸ | CA12 | O43570 | 1/20 | 0.51 |
| ▸ | CA1 | P00915 | 1/20 | 0.51 |
| ▸ | CA2 | P00918 | 1/20 | 0.51 |
| ▸ | CA9 | Q16790 | 1/20 | 0.51 |
| ▸ | MEN1 | O00255 | 1/20 | 0.51 |
| ▸ | ABL1 | P00519 | 1/20 | 0.51 |
| ▸ | LMNA | P02545 | 1/20 | 0.51 |
| ▸ | IDE | P14735 | 1/20 | 0.51 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.51 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.51 |
| ▸ | RIN1 | Q13671 | 1/20 | 0.51 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL15258705 | 1.00 | F2 (0.60) | F2PRSS1PRSS2PRSS3TPSAB1 | |
| SCHEMBL24313157 | 0.98 | F2 (0.60) | F2PRSS1PRSS2PRSS3TPSAB1 | |
| SCHEMBL10689008 | 0.98 | TDP1 (0.58) | F2PRSS1PRSS2PRSS3TPSAB1 | |
| SCHEMBL30062300 | 0.95 | F2 (0.65) | F2PRSS1PRSS2PRSS3TPSAB1 | |
| SCHEMBL1164840 | 0.95 | F2 (0.65) | F2PRSS1PRSS2PRSS3TPSAB1 | |
| SCHEMBL269540 | 0.95 | F2 (0.65) | F2PRSS1PRSS2PRSS3TPSAB1 | |
| SCHEMBL19679441 | 0.95 | F2 (0.65) | F2PRSS1PRSS2PRSS3TPSAB1 | |
| SCHEMBL30904598 | 0.94 | F2 (0.64) | F2PRSS1PRSS2PRSS3TPSAB1 | |
| SCHEMBL20042594 | 0.93 | TDP1 (0.62) | F2PRSS1PRSS2PRSS3TPSAB1 | |
| SCHEMBL20711508 | 0.93 | TDP1 (0.62) | F2PRSS1PRSS2PRSS3TPSAB1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 14 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20230381146-A1 | SUBSTITUTED HETEROARYL COMPOUNDS AND USE THEREOF | HELIOS HUAMING BIOPHARMA CO., LTD. (CN) | 2023-11-30 | — | — | US | disclosed |
| US-20230381146-A1 | SUBSTITUTED HETEROARYL COMPOUNDS AND USE THEREOF | HELIOS HUAMING BIOPHARMA CO., LTD. (CN) | 2023-11-30 | — | — | US | disclosed |
| US-20230381146-A1 | SUBSTITUTED HETEROARYL COMPOUNDS AND USE THEREOF | HELIOS HUAMING BIOPHARMA CO., LTD. (CN) | 2023-11-30 | — | — | US | disclosed |
| EP-3981772-A1 | TETRA-FUNCTIONAL CHEMICAL PROBE AND METHOD FOR IDENTIFYING TARGET MEMBRANE PROTEIN FROM LIVING CELL OR LIVING TISSUE BY USING SAID PROBE | Otsuka Pharmaceutical Co., Ltd. (JP) | 2022-04-13 | — | — | EP | disclosed |
| WO-2020246602-A1 | TETRA-FUNCTIONAL CHEMICAL PROBE AND METHOD FOR IDENTIFYING TARGET MEMBRANE PROTEIN FROM LIVING CELL OR LIVING TISSUE BY USING SAID PROBE | 大塚製薬株式会社 | 2020-12-10 | — | — | WO | disclosed |
| US-9766235-B2 | Trifunctional crosslinking reagents | ETH ZURICH (CH) | 2017-09-19 | — | — | US | disclosed |
| WO-2016181312-A1 | POLYCYCLIC EPOXIDES AND COMPOSITIONS THEREOF WITH ANTI-CANCER ACTIVITIES | VERSITECH LIMITED (CN) | 2016-11-17 | — | — | WO | disclosed |
| EP-2942351-B1 | TRIFUNCTIONAL CROSSLINKING REAGENTS | ETH ZUERICH (CH) | 2016-10-12 | — | — | EP | disclosed |
| EP-2670755-B1 | TRIFUNCTIONAL CROSSLINKING REAGENTS | ETH ZUERICH (CH) | 2016-10-12 | — | — | EP | disclosed |
| EP-2942351-A1 | TRIFUNCTIONAL CROSSLINKING REAGENTS | ETH Zurich (CH) | 2015-11-11 | — | — | EP | disclosed |
| US-20140171635-A1 | NOVEL HYDRAZONE-BASED AND OXIME-BASED FLUORESCENT AND CHROMOPHORIC/PRO-FLUORESCENT AND PRO-CHROMOPHORIC REAGENTS AND LINKERS | SOLULINK BIOSCIENCES, INC. (US) | 2014-06-19 | — | — | US | disclosed |
| US-20140011212-A1 | TRIFUNCTIONAL CROSSLINKING REAGENTS | ETH ZURICH (CH) | 2014-01-09 | — | — | US | disclosed |
| US-8541555-B2 | Hydrazone-based and oxime-based fluorescent and chromophoric/pro-fluorescent and pro-chromophoric reagents and linkers | SOLULINK BIOSCIENCES, INC. (US) | 2013-09-24 | — | — | US | disclosed |
| WO-2010135800-A1 | INHIBITING OXIDATION AND IMMOBILIZING BIOMOLECULES ON A HYDROGEN-TERMINATED CRYSTALLINE SILICON SUBSTRATE | NATIONAL RESEARCH COUNCIL OF CANADA (CA) | 2010-12-02 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230381146-A1 | SUBSTITUTED HETEROARYL COMPOUNDS AND USE THEREOF | SSB, BTK, PADI6 | F2 2954/4885PRSS1 273/4885PRSS2 599/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.